糖尿病足介入综合诊治临床指南(第五版)

2019-03-30 中国糖尿病足细胞与介入治疗技术联盟 介入放射学杂志.2019,28(3):205-216.

糖尿病足是糖尿病最常见的并发症之一,具有发病率高、致残率高、致死率高和治愈率低的特点,严重影响国人身体健康和生活质量,对其却一直没有统一的规范治疗方法。2015 年,中国糖尿病足细胞与介入治疗技术联盟制定糖尿病足介入综合诊治临床指南(第一版),填补了国内糖尿病足治疗规范的空白,对提高我国救治水平起到重要作用。近10 年来,随着诊断标准和治疗方式更新及国内外相关研究不断深入,联盟组织国内89 家单位

中文标题:

糖尿病足介入综合诊治临床指南(第五版)

发布日期:

2019-03-30

简要介绍:

糖尿病足是糖尿病最常见的并发症之一,具有发病率高、致残率高、致死率高和治愈率低的特点,严重影响国人身体健康和生活质量,对其却一直没有统一的规范治疗方法。2015 年,中国糖尿病足细胞与介入治疗技术联盟制定糖尿病足介入综合诊治临床指南(第一版),填补了国内糖尿病足治疗规范的空白,对提高我国救治水平起到重要作用。近10 年来,随着诊断标准和治疗方式更新及国内外相关研究不断深入,联盟组织国内89 家单位在第四版基础上进行新的修订。现颁布第五版指南,以进一步规范我国糖尿病足临床诊治。 

拓展指南:糖尿病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=糖尿病足介入综合诊治临床指南(第五版))] GetToolGuiderByIdResponse(projectId=1, id=a39a51c001e30514, title=糖尿病足介入综合诊治临床指南(第五版), enTitle=, guiderFrom=介入放射学杂志.2019,28(3):205-216., authorId=null, author=, summary=糖尿病足是糖尿病最常见的并发症之一,具有发病率高、致残率高、致死率高和治愈率低的特点,严重影响国人身体健康和生活质量,对其却一直没有统一的规范治疗方法。2015 年,中国糖尿病足细胞与介入治疗技术联盟制定糖尿病足介入综合诊治临床指南(第一版),填补了国内糖尿病足治疗规范的空白,对提高我国救治水平起到重要作用。近10 年来,随着诊断标准和治疗方式更新及国内外相关研究不断深入,联盟组织国内89 家单位, cover=, journalId=null, articlesId=null, associationId=1591, associationName=中国糖尿病足细胞与介入治疗技术联盟, associationIntro=, copyright=0, guiderPublishedTime=Sat Mar 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>糖尿病足是糖尿病最常见的并发症之一,具有发病率高、致残率高、致死率高和治愈率低的特点,严重影响国人身体健康和生活质量,对其却一直没有统一的规范治疗方法。2015 年,中国糖尿病足细胞与介入治疗技术联盟制定糖尿病足介入综合诊治临床指南(第一版),填补了国内糖尿病足治疗规范的空白,对提高我国救治水平起到重要作用。近10 年来,随着诊断标准和治疗方式更新及国内外相关研究不断深入,联盟组织国内89 家单位在第四版基础上进行新的修订。现颁布第五版指南,以进一步规范我国糖尿病足临床诊治。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>糖尿病</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=52dc21c001e231ca" title="2019 TES临床实践指南:老年糖尿病的治疗" target=_blank>2019 TES临床实践指南:老年糖尿病的治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=9a9081c001e20900" title="生酮饮食干预2型糖尿病中国专家共识(2019年版)" target=_blank>生酮饮食干预2型糖尿病中国专家共识(2019年版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=763ab1c001e0523f" title="2019 国际共识:接受SGLT抑制剂治疗的1型糖尿病患者糖尿病酸中毒风险管理" target=_blank>2019 国际共识:接受SGLT抑制剂治疗的1型糖尿病患者糖尿病酸中毒风险管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=20ed21c001e029c0" title="2019 AACE/ACE共识声明:2型糖尿病综合管理方案" target=_blank>2019 AACE/ACE共识声明:2型糖尿病综合管理方案</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=ee36e1c001e002fb" title="2019年ADA糖尿病医学诊疗标准解读" target=_blank>2019年ADA糖尿病医学诊疗标准解读</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=89287, tagName=糖尿病足介入), TagDto(tagId=12987, tagName=综合诊治)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5709, appHits=364, showAppHits=19, pcHits=4188, showPcHits=1742, likes=140, shares=10, comments=10, approvalStatus=1, publishedTime=Mon Apr 29 00:19:54 CST 2019, publishedTimeString=2019-03-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Apr 29 00:19:54 CST 2019, updatedBy=null, updatedName=null, updatedTime=Wed Jan 03 20:21:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=糖尿病足介入综合诊治临床指南(第五版))])
糖尿病足介入综合诊治临床指南(第五版)
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=809073, encodeId=aac78090e3fc, content=学习吧, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Sat Aug 15 07:19:56 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807924, encodeId=c33d80e9241f, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:33 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807923, encodeId=792080e923fe, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:30 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807922, encodeId=30d780e922e4, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:27 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807921, encodeId=4f6080e921d0, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:25 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-15 ms7000000127904807

    学习吧

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=809073, encodeId=aac78090e3fc, content=学习吧, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Sat Aug 15 07:19:56 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807924, encodeId=c33d80e9241f, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:33 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807923, encodeId=792080e923fe, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:30 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807922, encodeId=30d780e922e4, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:27 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807921, encodeId=4f6080e921d0, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:25 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=809073, encodeId=aac78090e3fc, content=学习吧, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Sat Aug 15 07:19:56 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807924, encodeId=c33d80e9241f, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:33 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807923, encodeId=792080e923fe, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:30 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807922, encodeId=30d780e922e4, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:27 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807921, encodeId=4f6080e921d0, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:25 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=809073, encodeId=aac78090e3fc, content=学习吧, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Sat Aug 15 07:19:56 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807924, encodeId=c33d80e9241f, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:33 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807923, encodeId=792080e923fe, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:30 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807922, encodeId=30d780e922e4, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:27 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807921, encodeId=4f6080e921d0, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:25 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=809073, encodeId=aac78090e3fc, content=学习吧, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Sat Aug 15 07:19:56 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807924, encodeId=c33d80e9241f, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:33 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807923, encodeId=792080e923fe, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:30 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807922, encodeId=30d780e922e4, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:27 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807921, encodeId=4f6080e921d0, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:20:25 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0